Skip to content
10-Q

Quarterly Report

ENDONOVO THERAPEUTICS, INC. ENDV

0001493152-22-014380

← back to feed
Filed
May 19, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 19, 2022 140.63M sh
Long Term Debt Q1 2022 · Mar 31, 2022 $7.35M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $59.98K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $85.94K
Current Liabilities Q1 2022 · Mar 31, 2022 $19.77M
Current Liabilities Q1 2022 · Dec 31, 2021 $17.7M
Total Liabilities Q1 2022 · Mar 31, 2022 $19.85M
Total Liabilities Q1 2022 · Dec 31, 2021 $17.78M
Current Assets Q1 2022 · Mar 31, 2022 $64.43K
Current Assets Q1 2022 · Dec 31, 2021 $94.86K
Total Assets Q1 2022 · Mar 31, 2022 $1.82M
Total Assets Q1 2022 · Dec 31, 2021 $2.01M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$289.95K
Stockholders Equity Q1 2022 · Mar 31, 2021 −$15.97M
Stockholders Equity Q1 2022 · Dec 31, 2020 −$14.37M
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.06
Eps Basic Q1 2022 · Mar 31, 2021 −$0.06
Net Income Q1 2022 · Mar 31, 2021 −$2.68M
Operating Income Q1 2022 · Mar 31, 2021 −$590.44K
Gross Profit Q1 2022 · Mar 31, 2021 $32.19K
Cost Of Revenue Q1 2022 · Mar 31, 2021 $2.52K
Revenue Q1 2022 · Mar 31, 2021 $34.72K